Eiger BioPharmaceuticals to Participate in Conferences in April

PALO ALTO, Calif. – March 26, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will present at upcoming investor, scientific, and orphan drug conferences in April.

  • C. Wainwright Global Life Science Conference at Grosvenor House in London, England. Eiger will present a corporate overview and business update with live webcast on April 8, 10:50 am – 11:10 am GMT. Eiger will host one-on-one meetings.
  • 17th Hepatitis Delta International Network (HDIN) Meeting at The International Liver Congress™ 2019 in Vienna, Austria. Eiger will present: “Lonafarnib: An Oral, First-in-Class, Prenylation Inhibitor in Phase 3 D-LIVR Study for HDV and Pegylated Interferon Lambda: A Better Tolerated Interferon in Phase 2 LIMT / LIFT Studies for HDV”; Oral Presentation, April 10, 4:30 pm – 7:30 pm CET, Room Lehar 2 – Congress Venue.
  • The International Liver Congress™ 2019 meeting in Vienna, Austria.  A late-breaker oral presentation will be presented: “End of Study Results from LIMT HDV Study: 36% Durable Virologic Response at 24 Weeks Post-Treatment with Pegylated Interferon Lambda Monotherapy in Patients with Chronic Hepatitis Delta Virus Infection”; PS-052, Parallel Session: Hepatitis B/D/E – Clinical Aspects of Viral Hepatitis, April 11, 4:45 pm – 5:00 pm CET.
  • World Orphan Drug Congress USA 2019 at the Gaylord National Harbor Hotel in Washington, DC. Eiger will present: “Expanded Access Programs – When It’s About Survival, the Transition from Study to EAPs Can’t Be Overmanaged”; April 12.

A live webcast of the H.C. Wainwright presentation will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the “Investors” tab.  A replay of the webcast will be available approximately one hour following the completion of the live event.

About Eiger
Eiger is a late stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases.  We innovate by developing well-characterized drugs in newly identified or novel targets in rare diseases.  Our mission is to systematically reduce the time and cost of the drug development process to more rapidly deliver important medicines to patients.

The company’s lead program is in Phase 3, developing lonafarnib, a first-in-class prenylation inhibitor for the treatment of Hepatitis Delta Virus (HDV) infection.  Eiger is also preparing an NDA and MAA for lonafarnib to treat Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies with plans to file in 2019.  For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Note Regarding Forward-Looking Statements
This press release contains “forward-looking” statements that involve substantial risks and uncertainties.  All statements other than statements of historical facts, including statements regarding our future financial condition, timing for and outcomes of clinical results, business strategy and plans and objectives for future operations, are forward looking statements.  These forward-looking statements include terminology such as “believe,” “will,” “may,” “estimate,” “continue,” “anticipate,” “contemplate,” “intend,” “target,” “project,” “should,” “plan,” “expect,” “predict,” “could,” “potentially” or the negative of these terms.  Forward looking statements are our current statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned clinical development, including plans to complete enrollment of our D-LIVR study by the end of 2019, submit an NDA and MAA for Progeria and progeroid laminopathies in 2019, timing of end of treatment data in our LIFT study and progress our Phase 3 study in HDV; our ability to transition into a commercial stage biopharmaceutical company; our ability to finance the continued advancement of our development pipeline products; and the potential for success of any of our product candidates.  These statements concern product candidates that have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA).  No representation is made as to their safety or effectiveness for the purposes for which they are being investigated.

Various important factors could cause actual results or events to differ materially from the forward-looking statements that Eiger makes, including the risks described in the “Risk Factors” sections in the Annual Report on Form 10-K for the year ended December 31, 2018 and Eiger’s periodic reports filed with the SEC.  Eiger does not assume any obligation to update any forward-looking statements, except as required by law.

Eiger BioPharmaceuticals

SOURCE Eiger BioPharmaceuticals, Inc.
Investors: Ingrid Choong, PhD
Email: ichoong@eigerbio.com
Phone: 1-650-619-6115

PDF Icon

See More Press Releases